Last updated: February 13, 2026
Overview of the Drug
NDC 00078-1238 corresponds to Nivolumab (Opdivo), used primarily in immunotherapy for various cancers, including non-small cell lung cancer, melanoma, and renal cell carcinoma. It was approved by the FDA in 2015 and marketed by Bristol-Myers Squibb.
Market Size and Growth
The global oncology immunotherapy market was valued at approximately $50 billion in 2021, with a compound annual growth rate (CAGR) of 8.5% projected through 2027[1]. Nivolumab holds a significant share within this segment, driven by expanding indications, increasing adoption, and novel combination therapies.
Current Market Penetration
- Nivolumab’s primary competitive landscape includes pembrolizumab (Keytruda), atezolizumab (Tecentriq), and durvalumab (Imfinzi).
- In 2022, Nivolumab generated approximately $7.8 billion in revenue globally, representing roughly a 15% market share in immune checkpoint inhibitors[2].
- The drug’s usage is highest in North America and Europe, with emerging markets showing rapid growth.
Pricing Landscape
- The average list price for nivolumab varies by indication and dosing. In the U.S., the wholesale acquisition cost (WAC) is roughly $13,000 per 40 mg vial.
- In practice, the negotiated net price is generally 40-60% lower due to rebates, discounts, and insurance negotiations.
- Cost per treatment course (e.g., for metastatic melanoma, typically 240 mg every 2 weeks for a year) is estimated to range from $70,000 to $150,000, depending on dosing and duration.
Price Projections
- The trend suggests slight downward pressure on prices owing to biosimilar development and patent expirations slated for 2028, primarily in the EU and certain U.S. patents[3].
- Biosimilar entrants, such as Relatlimab (Libtayo) and others, are projected to introduce competition, potentially decreasing prices by 10-20% over the next 3-5 years.
- Industry insiders forecast the average selling price (ASP) for nivolumab could decline from $13,000 to roughly $10,000 per 40 mg vial through 2030.
Regulatory and Patent Landscape
- Bristol-Myers Squibb holds broad patents covering nivolumab, with key patents expiring in 2028.
- The U.S. Biosimilar pathway has seen accelerated approval processes, with the first biosimilars expected in the 2025-2028 timeframe.
- Patent litigations and exclusivity extensions could influence the timing and extent of price reductions.
Long-term Market Potential
- The expansion into combination therapies and new indications like gastric and bladder cancers may sustain demand.
- Market analysts project global sales could reach $15 billion annually by 2030, assuming no major patent or regulatory setbacks[4].
Key Drivers and Risks
| Drivers |
Risks |
| Increasing adoption in first-line settings |
Patent expirations and biosimilar entry |
| Expanded indications and approvals |
Regulatory delays in emerging markets |
| Growth in combination therapy use |
Price pressures from healthcare payers |
Summary
Nivolumab remains a high-revenue immunotherapy asset, with stable demand driven by ongoing indications and expansion into new cancer types. Price points are expected to decline gradually over the next five years with biosimilar competition, but from a high base, maintaining significant revenue through 2030.
Key Takeaways
- The current U.S. list price for nivolumab is approximately $13,000 per 40 mg vial.
- Global revenue was approximately $7.8 billion in 2022, with a projected market size reaching $15 billion by 2030.
- Biosimilar competition beginning around 2028 may reduce prices by 10-20%.
- Patent protections extend until 2028, delaying biosimilar market entry.
- New indications and combination regimens could sustain demand beyond patent expiration.
FAQs
-
What factors most influence nivolumab pricing?
Insurance negotiations, development costs, competition, patent status, and acceptance of biosimilars.
-
When will biosimilars for nivolumab likely enter the market?
Around 2028, pending patent expirations and regulatory approvals.
-
How does the market competition impact current prices?
Competition, notably from pembrolizumab and forthcoming biosimilars, exerts downward pressure on prices and market share.
-
Which regions offer the highest revenue potential?
North America leads, followed by Europe and Asia-Pacific, with growth potential in emerging markets.
-
What are the primary drivers for nivolumab’s future sales?
Additional indications, combination therapies, and increased adoption due to efficacy.
References
[1] MarketsandMarkets, "Oncology Drugs Market," 2022.
[2] Bristol-Myers Squibb, "Full Year 2022 Financial Results," 2023.
[3] U.S. Patent and Trademark Office, Patent expirations for checkpoint inhibitors, 2028.
[4] GlobalData, "Immunotherapy Market Forecast," 2023.
